Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
Editas Medicine, a prominent genome editing company, announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 10:15 AM ET. The presentation will be webcast live on their website, with archived recordings available for 30 days post-event.
Editas focuses on utilizing CRISPR technologies to develop precise genomic medicines aimed at treating serious diseases globally.
- None.
- None.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET.
The event will be webcast live and may be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the event.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor Contact
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
FAQ
When will Editas Medicine present at the Barclays Gene Editing & Gene Therapy Summit?
Where can I watch the Editas Medicine presentation at the summit?
How long will the Editas Medicine summit presentation be available for viewing after the event?
What technologies does Editas Medicine focus on for genome editing?
What is the main goal of Editas Medicine?
